What is CircNova?
CircNova operates at the intersection of artificial intelligence and molecular biology. The company utilizes its proprietary NovaEngine to generate, analyze, and identify circular RNA sequences with high therapeutic potential. Unlike traditional linear RNA approaches, circular RNA offers increased stability and longevity, making it a promising candidate for addressing complex, undruggable disease targets. By leveraging machine learning to streamline the discovery process, CircNova aims to reduce the time and cost associated with bringing novel therapeutics to clinical trials, thereby addressing significant unmet needs in the healthcare sector.
How much funding has CircNova raised?
CircNova has raised a total of $3.3M across 1 funding round:
Angel/Seed
$3.3M
Angel/Seed (2025): $3.3M with participation from South Loop Ventures, Spark Capital, and Invest Detroit Ventures
Key Investors in CircNova
South Loop Ventures
South Loop Ventures is a Pre-Seed and Seed stage venture fund based in Houston, TX, investing in innovative founding teams aiming to reshape future economies across sectors like Healthtech.
Spark Capital
Spark Capital is a multi-stage venture firm with a history of backing transformative companies in technology and consumer products, operating out of San Francisco, Boston, and New York City.
Invest Detroit Ventures
Invest Detroit Ventures provides critical resources and strategic insights to entrepreneurs, focusing on fostering business growth and navigating the complexities of the startup ecosystem.
What's next for CircNova?
With this major strategic investment, CircNova is well-positioned to scale its NovaEngine platform and advance its lead candidates toward preclinical validation. The company's roadmap likely involves expanding its internal team of computational biologists and RNA experts to refine its predictive modeling capabilities. Furthermore, the firm is expected to seek strategic partnerships with larger pharmaceutical entities to validate its platform's efficacy in diverse therapeutic areas. As CircNova continues to mature, the focus will shift toward establishing a robust intellectual property portfolio and navigating the regulatory pathways required for future clinical development, ensuring that its innovative RNA-based solutions can eventually reach patients in need.
See full CircNova company page
